NASDAQ: INMB - INmune Bio, Inc.

Yield per half year: -42.38%
Dividend yield: 0.00%
Sector: Healthcare

Share chart INmune Bio, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About INmune Bio, Inc.

INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

more details
The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2019-02-04
ISIN US45782T1051
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.inmunebio.com
Цена ао 11.88
Change price per day: -1.69% (4.73)
Change price per week: +5.68% (4.4)
Change price per month: -4.91% (4.89)
Change price per 3 month: -10.92% (5.22)
Change price per half year: -42.38% (8.07)
Change price per year: -58.7% (11.26)
Change price per 3 year: -56.38% (10.66)
Change price per 5 year: +15.38% (4.03)
Change price per 10 year: 0% (4.65)
Change price per year to date: -20.51% (5.85)
All parameters

Underestimation

Title Value Grade
P/S 1220.37 1
P/BV 4.96 3
P/E 0 0
EV/EBITDA -5.51 0
Total: 2.63

Efficiency

Title Value Grade
ROA, % -52.64 0
ROE, % -78.68 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.3509 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % -99.8 0
Yield Ebitda, % 175.38 10
Yield EPS, % 87.52 9
Total: 7.8
More

Institutions Volume Share, %
Vanguard Group Inc 541329 3
Blackrock Inc. 257929 1.43
Rhenman & Partners Asset Management AB 178284 0.99
Geode Capital Management, LLC 170040 0.94
Janney Montgomery Scott LLC 163559 0.91
Deutsche Bank Aktiengesellschaft 109848 0.61
MAI Capital Management 98012 0.54
Quadrant Capital Group LLC 60000 0.33
Royal Bank of Canada 57791 0.32
State Street Corporation 45063 0.25

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.01798 17.09 1.54048
Vanguard Russell 2000 Growth ETF 0.01 23.05 0.60264
iShares Russell 2000 Growth ETF 0.0057 38.04 0.6026
ProShares UltraPro Russell2000 0.00138 89.82 1.47873
ProShares Hedge Replication ETF 0.00039 5.92 1.47892
Avantis U.S Small Cap Equity ETF 0.00028 27.77 1.68271
Vanguard Russell 3000 ETF 0 31.87 1.43817
Vanguard Russell 2000 ETF 0 17.16 1.48801



Head Job title Payment Year of birth
Dr. Raymond Joseph Tesi M.D. Co-Founder, President, CEO, Chief Medical Officer & Chairman 500.5k 1956 (69 years)
Mr. David J. Moss M.B.A. CFO, Treasurer & Secretary 394.9k 1970 (55 years)
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. Chief Scientific Officer & Chief Manufacturing Officer 150.24k 1963 (62 years)
Mr. Joshua S. Schoonover Esq. General Counsel N/A

Address: United States, Boca Raton. FL, 225 NE Mizner Blvd. - open in Google maps, open in Yandex maps
Website: https://www.inmunebio.com